Post by
SupermanLantern on Jan 14, 2016 12:35pm
article
older but talks about exactly what you guys are mentioning here:
https://marketexclusive.com/high-risk-high-reward-on-telestas-panel-review/1004/
I am convinced it will be approved on narrow label with continuous testing required.
Comment by
noinstinct89 on Jan 14, 2016 12:47pm
Our BCG refractory/relapsing is already narrowed.. So how to narrow a narrowed Label?
Comment by
Hatchchat on Jan 14, 2016 12:59pm
+1 MCNA will never suppress BCG, the US won't be self-defeating. If we narrow our already narrowed indication, the MKAP of 180 million dollars is all we will ever get. Means shareprice of 0.60.
Comment by
SteveMcM on Jan 14, 2016 5:05pm
Mackinnon, the $254M is peak sales, not expected until a few years after launch. The share price listed is a one-year target, reflective the lower sales estimate in earlier years.
Comment by
Hatchchat on Jan 14, 2016 6:40pm
now tell us mackinonn80 where do you see the most probable mkap after the most probable way of approval for you?
Comment by
blartar on Jan 14, 2016 2:01pm
pps re. CEO or COO getting canned over AdCom fiasco, Nobody gets canned @ TELESTA , they just get MORE OPTIONS !!!!!!
Comment by
ragingbull1234 on Jan 14, 2016 3:01pm
Why would the EXECUTIVES of TELESTA get canned? The FDA's AdCom should be cancelled across the board, because it's a corrupt and stupid idea to begin with. I'd fire the entire Food and Drug Administration and start with a new gameplan. WORK FASTER AND MORE ACCURATELY THAN THE LAST PEOPLE, OR WE WILL REPLACE YOU TOO, WITH EITHER PEOPLE OR COMPUTERS THAT CAN
Comment by
ragingbull1234 on Jan 14, 2016 5:35pm
I guess I'm just happy that I'm not old enough to actually believe that they need this much time. To do ANYTHING. if you cannot keep up, then please get out of the way